iBio appoints Dr. Martin Brenner as Interim CEO; Felipe Duran as Interim CFO

iBio, Inc.

Dr. Martin Brenner, previously CSO, appointed Interim CEO effective Jan. 20, 2023; receives $7,500/mo stipend plus 130,000 RSUs vesting over 12 months.
Felipe Duran, previously VP FP&A, appointed Interim CFO effective Feb. 13, 2023; base salary increased from $300K to $350K, eligible for $140K special incentive bonus.
Interim CEO appointment is temporary while board continues search for permanent CEO; Duran's additional retention bonus of $70K to remain through March 31, 2023.
Both positions are at-will; severance includes 9 months base salary without cause, 12 months with change in control, plus COBRA and equity acceleration.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed (interim)

Felipe Duran

Interim Chief Financial Officer

IBIO · iBio, Inc.

Effective: 2023-02-13
Filed: January 25, 2023, 6:59 PM ET

and Mr. Felipe Duran, to the position of Interim Chief Financial Officer, effective as of February 13, 2023

Appointed (interim)

Dr. Martin Brenner

Interim Chief Executive Officer

IBIO · iBio, Inc.

Effective: 2023-01-20
Filed: January 25, 2023, 6:59 PM ET

appointed Dr. Martin Brenner to the position of Interim Chief Executive Officer, effective immediately

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Felipe Duran was appointed as Interim Chief Financial Officer at iBio, Inc..

Action: appointed
Role: Interim Chief Financial Officer

Exact text from the filing

and Mr. Felipe Duran, to the position of Interim Chief Financial Officer, effective as of February 13, 2023

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Dr. Martin Brenner was appointed as Interim Chief Executive Officer at iBio, Inc..

Action: appointed
Role: Interim Chief Executive Officer

Exact text from the filing

appointed Dr. Martin Brenner to the position of Interim Chief Executive Officer, effective immediately

View on SEC.gov

iBio, Inc. filing history →

Source: SEC EDGAR

accession 0001420720-23-000004

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.